Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Revvity (RVTY)

NYSE: RVTY · Health Care Equipment · Waltham, MA

Our rating: Neutral

Neutral reaffirmed at $158.25, moderate conviction, November 11, 2026.

Breaks if: Neutral turns Cautious if revenue growth decelerates to below 2% in any two of the next three quarterly filings, or if trailing twelve-month free cash flow drops below $400M — either would signal the recovery thesis is stalling faster than the multiple can absorb. Neutral turns Positive if revenue growth prints above 8% for two consecutive quarters while net margin expands above 12%, demonstrating that earnings power is genuinely catching up to the valuation.

Key figures

Market value$16.2B
Revenue, last 12 months$2.9B
Net income, last 12 months$253M
Free cash flow, last 12 months$590M
Price to earnings64.0×
Free cash flow yield3.6%
Dividend yield0.2%
Operating margin12.6%
Return on equity3.5%
Beta to the S&P 5001.07
Volatility, annualized37.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
October 4, 2026$729M4.3%$0.56$152M
July 5, 2026$730M1.3%$0.47$181M
April 5, 2026$711M7.0%$0.36$95M
December 28, 2025$772M5.9%$0.86$162M
September 28, 2025$699M2.2%$0.40$120M
June 29, 2025$720M4.1%$0.46$115M
March 30, 2025$665M2.3%$0.35$112M
December 29, 2024$729M4.8%$0.78$150M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.